Business
Valerio Therapeutics Publishes Its 2025 Annual Results and Annual Financial Report, and Confirms the Strategic Transformation of Its Operating Model
VILLEJUIF, France, April 29, 2026--Regulatory News: Valerio Therapeutics (FR0010095596 – ALVIO), a biotechnology company specializing in the development of technology platforms dedicated to the targeted delivery of innovative therapies (the "Company"), today announces the publication of its annual results and annual financial report for the 2025 financial year, [available on its website under the "Financial Information" section], and outlines the key pillars of its strategic roadmap.
About this update from Valerio Therapeutics
[{"type":"list","items":[{"val":[{"type":"text","content":"Revenue: €2.6 million for the 2025 financial year, compared with €1.8 million in 2024 ","length":85,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Operating expenses: €4.8 million, compared with €18.3 million in 2024 ","length":69,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Creation of InVimmune, the Group’s first subsidiary in in vivo cell therapy, and execution of several partnership agreements during the financial year ","length":150,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":304,"olType":false},{"type":"text","content":"VILLEJUIF, France, April 29, 2026--(BUSINESS WIRE)--Regulatory News:","length":68,"tagName":"p"},{"type":"text","content":"Valerio Therapeutics (FR0010095596 – ALVIO), a biotechnology company specializing in the development of technology platforms dedicated to the targeted delivery of innovative therapies (the "Company"), today announces the publication of its annual results and annual financial report for the 2025 financial year, [available on its website under the "Financial Information" section], and outlines the key pillars of its strategic roadmap.","length":456,"tagName":"p"},{"type":"text","content":""2025 was a year of profound transformation for Valerio Therapeutics. We clarified our strategic direction, strengthened our scientific foundations and continued to validate our technology platforms. The Company’s strategy is built around three pillars: internal programs, partnerships/licensing, and the creation of subsidiaries. Our first subsidiary, InVimmune, represents an important milestone and opens up highly attractive opportunities in indications with significant unmet medical needs. At the same time, we continue to strengthen our teams and reinforce our expertise in order to accelerate the development of our technology platforms and pipeline. We believe that our talents, together with the network of experts surrounding Valerio, will enable the Company to achieve its objectives," said Julien Miara, Chief Executive Officer of the Company.","length":866,"tagName":"p"},{"type":"text","content":"Strategic refocusing","length":20,"tagName":"p"},{"type":"text","content":"Following the structural transformation of its operating model initiated in 2025, aimed at refocusing its a...